Denali Therapeutics Q1 net loss narrows as expenses fall

Denali Therapeutics

07/05/2026 21:49

Overview

Biotechnology firm's Q1 net loss narrowed yr/yr as operating expenses declined

Company received FDA approval and launched AVLAYAH for Hunter syndrome in U.S.

Denali received $200 mln from royalty funding deal; Takeda ended DNL593 collaboration

Outlook

Denali expects results from Phase 1/2 study of DNL593 for FTD-GRN by end of 2026

Company anticipates data from Phase 1b study of DNL628 for Alzheimer's in 1H 2027

Denali plans regulatory filing for DNL921 for Alzheimer's in 1H 2026

Result Drivers

AVLAYAH LAUNCH COSTS - Higher general and administrative expenses driven by increased headcount to support AVLAYAH commercial launch

R&D EXPENSE DECLINE - Lower research and development expenses mainly due to timing of AVLAYAH commercial supply manufacturing and reduced small molecule program costs

Company press release: ID:nGNXC82ly

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$128.45 mln
Q1 Basic EPS
-$0.69
Q1 Operating Expenses
$137.36 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Denali Therapeutics Inc is $39.00, about 91.1% above its May 6 closing price of $20.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)